Drug
Opevesostat
Opevesostat: highest development phase Phase 1/2, developed by Merck. 3 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Opevesostat NCT06353386 | Phase 1/2 | Prostatic Neoplasms, Castration-Resistant |
| Opevesostat NCT06104449 | Phase 1 | Prostatic Neoplasms |
| Opevesostat NCT06136598 | Phase 1 | Prostatic Neoplasms |
Latest
Follow Opevesostat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.